Immune Profiling to Determine Early Disease Trajectories Associated With Coronavirus Disease 2019 Mortality Rate: A Substudy from the ACTT-1 Trial

Joshua M. Thiede, Abigail R. Gress, Samuel D. Libby, Christine E. Ronayne, William E. Matchett, Brooke Noren, Joanne L. Billings, Vineet D. Menachery, Ryan A. Langlois, Susan Kline, Tyler D. Bold

Research output: Contribution to journalArticlepeer-review

Abstract

Coronavirus disease 2019 (COVID-19) outcomes are linked to host immune responses and may be affected by antiviral therapy. We investigated antibody and cytokine responses in ACTT-1 study participants enrolled at our center. We studied serum specimens from 19 hospitalized adults with COVID-19 randomized to treatment with remdesivir or placebo. We assessed severe acute respiratory syndrome coronavirus 2 antibody responses and identified cytokine signatures, using hierarchical clustering. We identified no clear immunologic trends attributable to remdesivir treatment. Seven participants were initially seronegative at study enrollment, and all 4 deaths occurred in this group with more recent symptom onset. We identified 3 dominant cytokine signatures, demonstrating different disease trajectories.

Original languageEnglish (US)
Pages (from-to)1339-1344
Number of pages6
JournalThe Journal of infectious diseases
Volume223
Issue number8
DOIs
StatePublished - Jan 21 2021

Bibliographical note

Publisher Copyright:
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Keywords

  • ACTT-1
  • COVID-19
  • cytokine
  • neutralization
  • remdesivir
  • serology
  • trajectory

Fingerprint

Dive into the research topics of 'Immune Profiling to Determine Early Disease Trajectories Associated With Coronavirus Disease 2019 Mortality Rate: A Substudy from the ACTT-1 Trial'. Together they form a unique fingerprint.

Cite this